Innovative Drug Developer Simcere Reports Falling Profits; Negotiates With Government Over Inclusion In National Insurance Catalogue
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Simcere Pharmaceutical Group posted lower-than-expected earnings for the third quarter of 2009 as the worldwide economic slowdown and limited health insurance coverage inside China hurt sales of the outfit's most innovative and expensive biopharmaceutical, according to Simcere's leadership
You may also be interested in...
China's Simcere Pharmaceutical Becomes Beacon For Disclosing GMP Problems At New Vaccine Subsidiary
BEIJING - Just weeks after acquiring a controlling equity stake in vaccine developer Jiangsu Yanshen, leading Chinese drug maker Simcere Pharmaceutical is pressing its new subsidiary to freeze production and replace two top executives that may have been responsible for lapses in good manufacturing practice standards at the vaccine facility
China's Simcere Pharmaceutical Becomes Beacon For Disclosing GMP Problems At New Vaccine Subsidiary
BEIJING - Just weeks after acquiring a controlling equity stake in vaccine developer Jiangsu Yanshen, leading Chinese drug maker Simcere Pharmaceutical is pressing its new subsidiary to freeze production and replace two top executives that may have been responsible for lapses in good manufacturing practice standards at the vaccine facility
Economic Slowdown Puts Brakes On Simcere’s Profits
BEIJING - Simcere Pharmaceutical Group posted lower-than-forecast earnings for 2008 due to the country's low rate of insurance coverage, combined with patients' cutting back on medical expenditures in the wake of the global recession, according to a senior executive